KlaAtlas ยท Dataset details
PXD062720
Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair
Back to datasets
6,978
Reidentified Kla sites
2,476
Reidentified Kla proteins
2
Raw MS files
Dataset overview
Dataset accession
Repository
PRIDE
Publication
UniProt taxonomy ID
9606
Sample category
Cell line
Tissue / cell type
UM-UC-3 bladder cancer cells isolated from cell-derived xenograft tumors
Experimental condition / comparison
Epirubicin-treated parental versus epirubicin-resistant UM-UC-3 CDX-derived cells.
Experimental information
Acquisition workflow
TIMS-DDA
MS platform
Bruker TIMS
Quantification strategy
Label-free
Kla enrichment method
Anti-L-lactyllysine antibody-conjugated agarose-bead immunoaffinity enrichment of lactylated peptides
Enrichment reagent supplier
PTM Bio, China
Reagent catalogue information
PTM-1404
Data access
MaxQuant parameter files
PXD062720_mqpar.xml
Raw MS file information
2 processed acquisition files.
Original raw data may be accessed
through the source repository.
Show raw MS file names (2 files)
- FE458LPLa_A_1_Slot1-34_1_14665.d
- FE458LPLa_A_3_Slot1-36_1_14669.d
Metadata sources
https://doi.org/10.1038/s41392-025-02302-y
https://www.ebi.ac.uk/pride/archive/projects/PXD062720
Methods: Identification of proteins with lysine lactylation by LC-MS/MS; PRIDE sample protocol
User-shared working sample map (conditional; not independently confirmed in primary archive): https://chatgpt.com/share/6adee875-f0e4-83e9-9d7e-5d6a2c369442
https://www.ebi.ac.uk/pride/archive/projects/PXD062720
Methods: Identification of proteins with lysine lactylation by LC-MS/MS; PRIDE sample protocol
User-shared working sample map (conditional; not independently confirmed in primary archive): https://chatgpt.com/share/6adee875-f0e4-83e9-9d7e-5d6a2c369442
Dataset notes
Sample information and limitations
Two selected acquisitions, one working-mapped A_1 and one A_3. The mapping source is user-shared information rather than an independent PRIDE confirmation; animal identity, pooling and biological/technical repetition remain unresolved. Only descriptive log2(A_3/A_1) direction is reported; no P value or FDR is valid from these files alone.
Experimental metadata notes
Epirubicin-treated parental versus epirubicin-resistant UM-UC-3 CDX-derived cells. Conditional working map used only for exploratory analysis, based on user-shared information and not independently confirmed in the article/PRIDE: A_1=parental+EPI; A_3=resistant+EPI. This is resistant-versus-parental under a shared EPI background, not EPI versus untreated.